Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab versus intensified infliximab in rheumatoid arthritis with fading response to infliximab
2005-001633-14Phase 4Terminated
- Sponsor
- Copenhagen University Hospital - Hvidovre
- Start
- Jun 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in rheumatoid arthritis (RA) comparing Adalimumab switch arm with Infliximab interval-shortening arm (2 arms). Primary endpoint: Combined good or moderate EULAR response at week 24. Started Jun 2005; status: terminated.
02
Drugs
adalimumabinfliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2005-001633-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001633-14.